JAK2 and systemic lupus erythematosus: The goal of this study was to characterise the molecular pathways impacted by the pharmacological effects of the JAK1 and JAK2 inhibitor baricitinib in SLE using RNA and serum samples from a phase II study of baricitinib that successfully met its primary endpoint.